Year: 2022

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and nine months ended September 30, 2022 and provided a business update. “We are excited about the advancement of ATRN-119, the first macrocyclic ATR inhibitor, into clinical development,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “We look forward to collecting clinical data from our Phase 1 trial.” Third Quarter Financial ResultsCash and cash equivalents:  As of September 30, 2022, the Company had $33.1 million of cash and cash equivalents compared to $53.1 million of cash and cash equivalents as of December...

– Third Quarter Revenues and Share of NPI Revenues Interest total $73.3 million, up 262% year-over-year – – Improves Full Year 2022 Revenue and Share of NPI Revenues Guidance to $197 million to $208 million – LUXEMBOURG, Nov. 09, 2022 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery and iGaming solutions, announced today financial results for the third quarter ended September 30, 2022, the first full quarter after the completion of the Aspire Global combination. Moti Malul, Chief Executive Officer of NeoGames, said: “The strong performance where we grew revenue and profitability across the business is a great start for our first full quarter post completion of the combination. In iLottery, our top line results grew 22% compared to last...

Established recommended Phase 2 dose (RP2D) for NBTXR3 plus anti-PD-1 in patients with locoregional recurrent and recurrent and/or metastatic head and neck cancer, lung metastases from any primary tumor, or liver metastases from any primary tumor Updated Phase 1 NBTXR3 plus anti-PD-1 safety and efficacy data in recurrent and/or metastatic advanced cancers from Study 1100 to be presented at SITC 2022 on November 10th Bolstered NBTXR3 strategic development capability with the appointment of twelve global medical experts to the Nanobiotix Scientific Advisory Board €53.5 million in cash and cash equivalents extends cash runway into Q1 2024PARIS and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based...

Provides Updated Full Year 2022 Outlook RICHARDSON, Texas, Nov. 09, 2022 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the third quarter ended October 1, 2022. Third Quarter SummaryThird quarter worldwide net sales totaled $436 million, decreasing 11% on a reported basis and 5% in constant currency. From a regional lens, Americas and Asia sales declined while Europe was flat on a constant currency basis.Direct to consumer net sales increased 5% in constant currency, led by growth in retail store sales and owned websites.FOSSIL brand sales grew in leathers, traditional watches and jewelry, offset by declines in smartwatches, resulting in a total sales decline of 2% in constant currency.Operating income of $22 million compared to $48 million a year ago. Adjusted operating income...

Successfully Completed Upsized Initial Public Offering Providing Funding Through 2025 Patient Dosing Underway in Phase 1b Chronic Inducible Urticaria Clinical Trial CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation, today announced financial results for the quarter ended September 30, 2022 and provided a corporate update. “With the recent close of our successful initial public offering, we believe we have the capital resources and experienced team in place to advance the continued development of THB001 for the treatment of urticaria, or chronic hives, and asthma – two inflammatory diseases where, despite current treatment options, a significant unmet medical...

$899 million net sales, including ($45) million FX impact; +14% y/y as reported, second highest quarterly revenue Net sales +19% y/y in Constant Currency (“CC”)(a) Thin Plate Pure Lead (TPPL) revenue approx +30% Adj GM +120 bps sequentially as price/mix improvements eclipsed sequential cost increases $1.4 billion backlog, +38% y/y, remains healthy supported by robust demand and order trends across all segments Ooltewah plant closure and transition to Richmond executing as planned; on track for ~$8 million annual cost savings Successfully launched NexSys® customer day featuring TPPL and lithium-ion line tours with 300 key decision makers $4 million/yr capex allocated to our sustainability goals FY’24 and beyondREADING, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) — EnerSys (NYSE: ENS), the global leader in stored energy...

We’re making the world of next-gen, battery technology cooler, lighter, and safer!Join the battery revolution with KULR.SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) —  KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today reported results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results  Revenues: In the third quarter ended September 30, 2022, revenue increased to $1.4 million from $0.6 million reported in the same period last year. The increase in revenue was primarily due to an increase in contract services and product sales revenues in the quarter. Cash: As of September 30, 2022, the Company had...

FutureFuel Third Quarter Net Income of $15.8 Million Reports Net Income of $15.8 Million or $0.36 per Diluted Share, and Adjusted EBITDA of $14.8 Million CLAYTON, Mo., Nov. 09, 2022 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE:FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the third quarter ended September 30, 2022. Third quarter 2022 Financial Highlights (all comparisons are with the third quarter of 2021)Revenues were $118.1 million, up 20% from $98.7 millionAdjusted EBITDA was $14.8 million, up from $11.1 million (see reconciliation table below)Net income was $15.8 million, or $0.36 per diluted share, up 71% from net income of $9.2 million, or $0.21 per diluted share.Nine months 2022 Financial Highlights (all comparisons are with the first nine...

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurrent endometrial cancer ONA-XR continues to exhibit favorable safety and tolerability profile Cash and cash equivalents of $39 million as of September 30, 2022, expected to provide runway into Q1 2024 PHILADELPHIA, Nov. 09, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2022. “We are pleased with the continued strengthening...

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ($0.22 per basic and $0.20 per diluted share), which Includes a One Time Charge of $4.1 Million Related to the Acquisition of Ruzurgi® Cash and Short-Term Investments Increased in Q3 2022 by $35.3 Million to $256.1 Million Non-GAAP Net Income for Q3 2022 of $28.6 Million ($0.28 per basic share and $0.26 per diluted share) Company to Host a Conference Call and Webcast on November 10, 2022, at 8:30 AM ET CORAL GABLES, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel...